History

2016

  • Strekin concludes licensing agreement with Roche, ensuring exclusive global rights for development of pamapimod, a phase 2 clinical P38 MAPK inhibitor

  • Development of KIN001, a unique small molecule therapeutic

  • Initial preclinical models for KIN001 trigger selection of disease indications for clinical development

2017

  • Pamapimod licence, KIN001 as well as corresponding data carved-out from Strekin

  • Kinarus AG founded based on those assets

  • First financing round with private investors with proceeds used to support clinical development

  • Kinarus files patents for KIN001 in multiple indications

2018

  • Kinarus receives regulatory and ethics committee approval to launch phase 2 clinical trial of KIN001 in wet AMD as an oral therapy complementing anti-VEGF agents with the objective to extend duration between required injections

  • Kinarus completes clinical protocol for complementary phase 2 trial in Idiopathic Pulmonary Fibrosis (IPF), ready for regulatory submission

2019

  • Composition of Matter patent granted in Europe (US decision pending) for KIN001

  • Second financing with private investors with proceeds used to fund the clinical development of KIN001 as well as general corporate purposes

2020

  • Kinarus generates data demonstrating potent anti-viral activity of KIN001 against Sars-CoV-2

  • Kinarus capitalizes on KIN001 as a potentially effective COVID-19 therapy, with the advantage of targeting multiple facets of the disease given the drugs’ antiviral, anti-inflammatory, and antifibrotic activities

2021

  • Kinarus receives approval from German regulatory authority to start large phase 2 clinical trial (approx. 400 patients) for the treatment of hospitalized COVID-19 patients

  • Third financing from private investors as well as CHF 3.0 Mio convertible loan secured used to fund the phase 2 trial of KIN001 in COVID-19 as well as the related clinical development plans

  • Kinarus prepares Scientific Advice (EMA) and pre-IND meeting (FDA) for agreement on clinical and technical development and launch strategy in Europe and the US

  • First patients dosed in Phase 2 clinical trial of KIN001 for oral treatment of hospitalized COVID-19 patients

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok